• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Fentanyl pre-treatment does not affect the pharmacokinetic profile of an induction dose of propofol in adults.

作者信息

De Gasperi A, Cristalli A, Noé L, Sabbadini D, Mazza E, Prosperi M, Fantini G, Crespi A M, Rezzani S

机构信息

II Servizio di Anestesia, Ospedale Niguarda Ca' Granda, Milan, Italy.

出版信息

Eur J Anaesthesiol. 1994 Mar;11(2):89-93.

PMID:8174540
Abstract

The initial disposition of propofol was reported to change when the administration was preceded by fentanyl. The pharmacokinetic profile of the induction dose of propofol (2 mg kg-1 body weight) was studied in 20 ASA I patients randomly allocated to receive fentanyl 1.5 microgram kg-1 (n = 12) or not (n = 8). Anaesthesia was maintained with isoflurane in N2O/O2. Venous blood drawn from the contralateral arm was used to determine whole blood propofol concentrations. The mean propofol blood concentrations were comparable in the two groups and were best fitted by a three exponential equation in all the patients, conforming to a three-compartment open mammillary model. Distributions (T1/2 alpha) redistribution (T1/2(7)) and elimination (T1/2 beta half-lives were comparable in the groups, without significant differences in the total body clearance in the area under the time-concentration curve (zero-infinity) in the volume of distribution at steady-state, in the volume of distribution during the elimination phase or in the mean resident time. Our data support the conclusion that pretreatment with fentanyl does not affect the pharmacokinetic profile of the induction dose of propofol in ASA I patients.

摘要

相似文献

1
Fentanyl pre-treatment does not affect the pharmacokinetic profile of an induction dose of propofol in adults.
Eur J Anaesthesiol. 1994 Mar;11(2):89-93.
2
Pharmacokinetic profile of the induction dose of propofol in chronic renal failure patients undergoing renal transplantation.肾移植慢性肾衰竭患者中丙泊酚诱导剂量的药代动力学特征。
Minerva Anestesiol. 1996 Jan-Feb;62(1-2):25-31.
3
Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.丙泊酚与芬太尼的药代动力学相互作用:单次推注研究。
Br J Anaesth. 1990 Dec;65(6):760-5. doi: 10.1093/bja/65.6.760.
4
Disposition of propofol administered as constant rate intravenous infusions in humans.丙泊酚以恒速静脉输注方式给药在人体中的处置情况。
Anesth Analg. 1987 Dec;66(12):1256-63.
5
[Effects of speed of injection on anesthesia induction with propofol and fentanyl].[注射速度对丙泊酚与芬太尼麻醉诱导的影响]
Masui. 1999 Aug;48(8):847-51.
6
Pharmacokinetics of propofol in mixed-breed dogs and greyhounds.
Am J Vet Res. 1993 May;54(5):755-60.
7
Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults.
J Anesth. 2000;14(3):124-7. doi: 10.1007/s005400070018.
8
Fentanyl pre-treatment alleviates pain during injection of propofol-lipuro premixed with lignocaine.芬太尼预处理可减轻与利多卡因预混的丙泊酚乳剂注射时的疼痛。
Med J Malaysia. 2008 Dec;63(5):431-3.
9
[Success rate of anesthesia induction using target-controlled infusion of propofol with fentanyl].[使用丙泊酚与芬太尼靶控输注进行麻醉诱导的成功率]
Masui. 1999 Mar;48(3):256-9.
10
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.丙泊酚用于重症患者长期镇静的群体药代动力学和药效学建模:丙泊酚6%与丙泊酚1%的比较
Clin Pharmacol Ther. 2002 Dec;72(6):670-84. doi: 10.1067/mcp.2002.129500.

引用本文的文献

1
Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.丙泊酚。其药理学概述及在重症监护镇静中临床疗效的综述。
Drugs. 1995 Oct;50(4):636-57. doi: 10.2165/00003495-199550040-00006.
2
Propofol. An update of its use in anaesthesia and conscious sedation.丙泊酚。其在麻醉和清醒镇静中应用的最新情况。
Drugs. 1995 Sep;50(3):513-59. doi: 10.2165/00003495-199550030-00008.